Trial Profile
A Phase II Trial to Evaluate the Safety and Activity of Single-Agent Lenalidomide Given as Maintenance Therapy After Response to Second-Line Therapy in Patients With Relapsed DLBCL, Not Eligible for High-Dose Chemotherapy and ASCT.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 01 Aug 2020 Final results assessing long-lasting efficacy and safety published in the Hematological Oncology
- 04 Dec 2018 Results reporting efficacy and safety results of the trial after a median follow-up of 56 months, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.